ArticleJHLT open2026
Maximizing cardiopulmonary support as a minimally invasive platform-using peripheral parallel veno-venous and veno-arterial extracorporeal membrane oxygenation and axillary impella 5.5 as a bridge to heart-lung transplantation.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined heart-lung transplantation (HLTx) in patients with cardiopulmonary failure requiring extracorporeal membrane oxygenation (ECMO) presents a major physiologic challenge. Conventional ECMO strategies may inadequately address simultaneous refractory hypoxemia, circulatory failure, and left ventricular (LV) distension without central cannulation and sternotomy. A 65-year-old man with severe heart failure (LVEF <10%) and rapidly progressive interstitial lung disease presented with cardiogenic shock and hypercapnic hypoxemic respiratory failure. Initial V-AV ECMO provided stabilization and allowed extubation and expedited HLTx evaluation. Progressive hypoxemia and acute kidney injury despite maximal V-AV support prompted escalation to peripheral parallel VV-VA ECMO. Echocardiography demonstrated LV distension, prompting axillary Impella 5.5 placement for decompression. The patient remained awake and extubated on parallel VV-VA ECMO and Impella 5.5 for 60 hours prior to successful heart-lung transplantation. We report the novel application of a fully peripheral cardiopulmonary support platform as a viable bridge strategy for HLTx candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.